Ginkgo Bioworks Holdings, Inc. (DNA) is a publicly traded Healthcare sector company. As of May 20, 2026, DNA trades at $7.74 with a market cap of $481.44M and a P/E ratio of -1.42. DNA moved +4.76% today. Year to date, DNA is -12.97%; over the trailing twelve months it is -3.38%. Its 52-week range spans $5.00 to $17.58. Analyst consensus is sell with an average price target of $8.50. Rallies surfaces DNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Ginkgo Bioworks Holdings, Inc. (DNA) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. DNA moved +4.76% today. Analyst consensus is sell.
| Metric | Value |
|---|---|
| Price | $7.74 |
| Market Cap | $481.44M |
| P/E Ratio | -1.42 |
| EPS | $-5.36 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.58 |
| 52-Week Low | $5.00 |
| Volume | 617.81K |
| Avg Volume | 0 |
| Revenue (TTM) | $141.31M |
| Net Income | $-304.39M |
| Gross Margin | 0.00% |
3 analysts cover DNA: 0 strong buy, 1 buy, 0 hold, 2 sell, 0 strong sell. Consensus rating is sell. Average price target: $8.50.